MedWarn.org
  • Alerts
  • Drugs
    • ADHD Medications
    • Allergy Treatments
    • Antidepressants
    • Antipsychotics
    • Antibiotics
    • Antiseizure
    • Arthritis
    • Cancer Treatments
    • Cardiovascular
    • Diabetes Treatments
    • Dietary Supplements/Weight Loss
    • Erectile Dysfunction
    • Gastrointestinal
    • Hormone Therapy
    • Oral Contraception
    • Pain Relief
    • Respiratory
    • Skin Conditions
    • Sleep
  • Vaccines/Biologics
    • Blood Products
    • Genetic Testing
    • Tissues
    • Vaccines
  • Devices
    • 3D Printed
    • Autoinjectors
    • Brain Devices
    • Breast Implants
    • Cardiac Devices
    • Contraceptive Devices
    • Cyber Security
    • Home Health Devices
    • Hip Implants
    • Infusion Pumps
    • Respiratory Systems
    • Stents
    • Surgical Devices
    • Transvaginal Mesh
  • Tobacco
  • Resources
    • Product Safety and the FDA
    • Product Recalls
    • Product Liability Lawsuits
    • Questions For A Lawyer
    • Get Help
  • About Us

Alerts, Recalls, and Legal Headlines

Sign-up to receive recall notices, medical news, and litigation updates.

SIGN-UP

FDA Warns Sleep Drug Lunesta Can Cause Next-Day Impairment

5/17/2014

0 Comments

 
Picture
The FDA is warning that the sleep aid Lunesta (eszopiclone) can cause next-day impairment of driving and other activities that require alertness.  As a result, the FDA has decreased the recommended starting dose of Lunesta from 3 mg at bedtime to 1 mg at bedtime.  Lunesta is a sedative-hypnotic sleep medicine used to treat insomnia in adults.  A recent study found that the previously recommended starting dose of 3 mg can cause impairment of driving skills, memory and coordination that can last more than 11 hours after receiving an evening dose.  The new lower recommended dose will result in less drug in the blood the next day.  The FDA recommends that patients continue to take their prescribed dose and contact their doctors to ask about the most appropriate dose for them.

[1] FDA Safety Announcement, "FDA Drug Safety Communication: FDA warns of next-day impairment with sleep aid Lunesta (eszopiclone) and lowers recommended dose" May 15, 2014. 

0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Archives

    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    September 2013
    July 2013
    June 2013
    May 2013
    March 2013
    January 2013
    July 2012
    June 2012
    March 2012
    February 2012
    August 2011
    December 2010
    August 2010
    February 2009
    July 2008

    RSS Feed

    Categories

    All
    3D Printing
    3D Printing
    Acid Reducers
    Acne Treatments
    ADHD
    Allergies
    Antibiotics
    Antidepressants
    Anti-Epilepsy
    Antipsychotics
    Antiviral
    Arthritis
    Aspirin
    Asthma
    Autism
    Birth Control
    Birth Defects
    Blood Products
    Bone
    Brain
    Cancer
    COPD
    Cyber Crime
    Diabetes
    Dietary Supplements
    Dna-testing
    E-cigarettes
    Electronic Health Records
    Eliquis
    Epilepsy
    FDA/Approvals
    FDA Recalls
    FDA/Recalls
    FDA Warnings
    FDA Warnings
    Hearing-devices
    Hearing Loss
    Heart
    Hemophilia
    Hip Implants
    Hormone
    HPV
    Infants
    Infusion Pump
    Invokana
    Legal News
    Migraines
    Mirena
    Monitors
    Multiple Sclerosis
    Pain Relief
    Research
    Resuscitation
    Risperdal
    Sleep
    Stents
    Stroke
    Surgical Device
    Surgical Device
    Topamax
    Transvaginal Mesh
    Vaccine
    Weight Control
    Weight Control

    RSS Feed



    120x600
Powered by Create your own unique website with customizable templates.
Photos used under Creative Commons from Official U.S. Navy Imagery, madaise, outcast104, archibald jude, Vee-vee